On October 30, the domestic medical device giant Mindray Medical released the third quarter report this year. According to the data, Mindray Medical's revenue during the reporting period was 3.471 billion yuan, a year-on-year increase of 20.97%; the net profit attributable to shareholders of listed companies was 1.025 billion yuan, a year-on-year increase of 30.01%. On October 16 this year, Mindray Medical was listed on the GEM, with an initial public offering of approximately 122 million shares, and the issue price per share was 48.80 yuan. After deducting the relevant expenses, it actually received about 5.796 billion yuan of raised funds. As of 11:00 on October 30, Mindray Medical's market value has exceeded 115.1 billion yuan, becoming the leading domestic medical equipment leader. Mindray Medical's main products cover three major areas, namely life information and support, in vitro diagnostics and medical imaging. In 2017, Mindray Medical's main business income was 11.132 billion yuan, and life information and support, in vitro diagnostics and medical imaging accounted for 38.05%, 33.60%, and 26.37%. In recent years, the state's policy dividend for domestic medical devices, Mindray Medical expects that the annual operating income in 2018 will be 13 billion yuan - 14.3 billion yuan, an increase of 16.34% - 27.98% over the same period of the previous year. From the beginning of this year to the end of the reporting period, Mindray Medical's revenue has reached 10.28 billion yuan, an increase of 23.19% over the same period of the previous year. If you want to achieve the revenue target of 13 billion yuan - 14.3 billion yuan this year, Mindray Medical needs at least 2.72 billion yuan in revenue in the fourth quarter. Referring to the second quarter of 2017, the revenue of 2.83 billion yuan, the billion euro health speculation, Mindray Medical completed this year's full-year target is not difficult. In addition, the third quarter report analysis, performance growth also benefited from the development of Mindray medical market. In the third quarter, Mindray Medical's sales expenses reached 821 million yuan, an increase of 29.09% compared with the previous period. On the other hand, Mindray Medical's ability to control fees has improved. During the reporting period, the administrative expenses were 179 million yuan, an increase of only 0.08 billion yuan from the previous period of 171 million yuan. It is worth noting that during the reporting period, Mindray Medical R&D expenses were 329 million yuan, an increase of 63.68% compared with the previous period; from January to September, Mindray Medical has invested 969 million yuan in research and development. Compared with the same period last year, it increased by 28.49%. According to public data, Mindray's annual R&D investment accounts for more than 10% of its operating revenue, which exceeds the total R&D investment of other A-share listed medical device companies. For a long time before, the market share of domestic medical devices was almost completely occupied by foreign products. However, as the country has continuously introduced a new policy in recent years, the process of “domestic replacement imports†for medical devices has gradually accelerated. Since 2017, the five provinces and cities of Zhejiang, Sichuan, Guangdong, Shanghai and Jiangsu have been included in the first batch of pilot projects to support domestic medical equipment , and the policy has been promoted. Wang Baoting, deputy secretary-general of the China Drug Administration Research Association, said that China has become one of the major producers and major consumers of medical devices in the world. By 2020, the annual total sales in China is expected to exceed 700 billion yuan in the next 10 years. The average growth rate is over 10%, and the market demand will further enhance the vitality of domestic medical device companies. According to the National Bureau of Statistics, the total export value of medical instruments and devices in China was US$9.363 billion in 2016, and the compound growth rate has reached 9.27% ​​since 2010. The layout of Mindray Medical in the international market is also accelerating. According to the data, Mindray Medical has carried out excessive mergers and acquisitions in the past few years. In 2008, Mindray Medical acquired the US Datascope's monitoring business; from 2011 to 2013, it also acquired Shenmailui Technology, Suzhou Huisheng, Zhejiang Wang Greenland, Changsha Tiandi, Hangzhou Guangdian, Wuhan Dejibaier, Shanghai Medical Ten companies including Guang, Zonare, Ulco, and Beijing Pulisheng; in 2014, I purchased Shanghai Long Island. The international market has become an important direction for the future development of Mindray Medical. TUR Drape,Sterile TUR Drape,Surgical TUR Drape,Disposable TUR Drape Xinxiang Huaxi Sanitary Materials Co., Ltd. , https://www.huaximedical.com